GGrantIndex
← Search

Cancer Research Career Enhancement and Related Activities

$58,926P30FY2023CANIH

Mayo Clinic Rochester, Rochester MN

Investigators

Linked publications, trials & patents

Trial NCT06508463Trial NCT06387979Trial NCT06381154Trial NCT06353191Trial NCT06315595Trial NCT06271291Trial NCT06238648Trial NCT06207188Trial NCT06160206Trial NCT06115772Trial NCT06078709Trial NCT06075524Trial NCT06073951Trial NCT06058663Trial NCT05917145Trial NCT05910801Trial NCT05720624Trial NCT05717153Trial NCT05704283Trial NCT05703399Trial NCT05674123Trial NCT05653661Trial NCT05640765Trial NCT05612100Trial NCT05591092Trial NCT05584449Trial NCT05575440Trial NCT05560009Trial NCT05557877Trial NCT05556525Trial NCT05549661Trial NCT05547386Trial NCT05547347Trial NCT05541016Trial NCT05530759Trial NCT05526417Trial NCT05523154Trial NCT05518903Trial NCT05512767Trial NCT05507879Trial NCT05507541Trial NCT05497804Trial NCT05465954Trial NCT05465941Trial NCT05447923Trial NCT05447910Trial NCT05443971Trial NCT05438563Trial NCT05417867Trial NCT05416983Trial NCT05412953Trial NCT05411523Trial NCT05411497Trial NCT05410977Trial NCT05407038Trial NCT05407025Trial NCT05403580Trial NCT05399004Trial NCT05393713Trial NCT05392946Trial NCT05388877Trial NCT05388851Trial NCT05388058Trial NCT05388006Trial NCT05356897Trial NCT05294367Trial NCT05288062Trial NCT05269381Trial NCT05246670Trial NCT05232851Trial NCT05224271Trial NCT05222620Trial NCT05212428Trial NCT05199285Trial NCT05194293Trial NCT05176223Trial NCT05168163Trial NCT05130060Trial NCT05112627Trial NCT05112614Trial NCT05111314Trial NCT05077735Trial NCT05075980Trial NCT05053100Trial NCT05045066Trial NCT05033288Trial NCT05030298Trial NCT05018208Trial NCT05005182Trial NCT04999826Trial NCT04975516Trial NCT04967196Trial NCT04926948Trial NCT04925817Trial NCT04917744Trial NCT04906369Trial NCT04897009Trial NCT04895735Trial NCT04892277Trial NCT04892264

Abstract

CANCER RESEARCH CAREER ENHANCEMENT AND RELATED ACTIVITIES PROJECT SUMMARY The Mayo Clinic Cancer Center (MCCC) embraces career enhancement and education as one of its core missions. NIH-funded training mechanisms and Mayo Clinic philanthropy support cancer researchers at all career levels. Faculty and trainees benefit from MCCC seminars and conferences that provide ongoing state-of-the-art education updates. The specific aims of the MCCC Career Enhancement and Related Activities are as follows: 1) to mentor and develop the next generation of high-achieving cancer researchers, and 2) to provide MCCC trainees and faculty with continuing research and medical education to further their career development and to support the MCCC mission of improving cancer prevention, detection, diagnosis, and therapy. The MCCC is well-positioned to accomplish these aims, as demonstrated by its 1) 12 NIH-funded training programs whose trainees have amassed 600+ cancer-focused publications this past grant cycle; 2) 13 competitive, philanthropically- funded, MCCC grant mechanisms that award $50,000 to $100,000 of annual support to each junior investigator 3) the competitive, philanthropically-funded Eagles mechanism that annually awards over $500,000 in direct research funding, primarily to junior cancer investigators; 4) career development opportunities within the MCCC's SPORE's, which forge strong alignment between MCCC research priorities and the interests of junior investigators; 5) institutional salary subsidization of trainees on K awards ($20M allocated since 2012 to cancer researchers) and financial incentives for junior MCCC trainees to apply for NIH funding, both of which are intended to retain junior cancer investigators within academic medicine; and 6) a commitment to diversity that permeates the MCCC's career enhancement and educational efforts and that allows the MCCC to train, to recruit, and to promote high-achieving cancer researchers. In view of its commitment to career enhancement and education, the MCCC is poised to accomplish its specific aims and to train the next generation of cancer researchers who will conduct ground-breaking research that will improve the lives of cancer patients.

View original record on NIH RePORTER →